Key Highlights

  • Affimed's shares have collapsed to a fraction of a cent and now change hands over the counter under a ticker carrying the Q suffix associated with distressed or bankruptcy-linked names.
  • The company's innate cell-engager platform historically included lead candidates AFM13 and AFM24, tested in lymphoma and solid tumors.
  • Affimed filed extensively with the SEC as a foreign private issuer for years after its 2014 IPO, but its listing has since moved from Nasdaq to over-the-counter trading.
  • AFMDQ traded near $0.0001 with a Market Value in the low four figures in the last closing session, with no verified financing, clinical readout, or Partnership explaining the price.

Affimed N.V. (OTC:AFMDQ) is a cautionary chapter in immuno-oncology. Once a Nasdaq-listed developer of innate-immunity cancer therapies with a well-followed pipeline, the company's shares have collapsed to a fraction of a cent and now change hands over the counter under a ticker carrying the Q suffix conventionally associated with distressed or bankruptcy-linked names.

Company and Latest Development

Affimed, headquartered in the Heidelberg-Mannheim region of Germany, is a clinical-stage biopharmaceutical company built around its innate cell-engager platform, with lead candidates historically including AFM13 and AFM24 in trials for lymphoma and solid tumors. It filed extensively with the SEC as a foreign private issuer, submitting annual 20-F reports and 6-K updates for years after its 2014 IPO.

The company's public filing cadence and market standing have since deteriorated sharply, and its listing has moved from Nasdaq to over-the-counter trading, a transition that typically follows loss of exchange compliance amid financial distress.

What Is Driving Attention Around AFMDQ?

The attention is structural, not catalyst-driven. AFMDQ trades near $0.0001 with a market value in the low four figures, and there is no verified recent development, no financing, clinical readout, partnership or regulatory event, that explains its current pricing.

The Q-style ticker and the move to OTC are themselves the signal: they point to severe financial strain rather than to any fresh Business milestone. In distressed situations like this, quoted prices reflect capital-structure realities far more than pipeline value.

Key Numbers and Company Position

Verifiable current figures are limited and should be read with caution. Aggregated data show a quoted price around $0.0001 and a market Capitalization measured in the low thousands of dollars, a collapse from the company's former valuation.

Trailing figures cited by aggregators include a steep Revenue decline and a large net loss, consistent with a clinical-stage company that has lost collaboration-driven income and continued to burn cash. Given the distressed status, historical audited filings are more reliable than any current market-derived snapshot.

What Could Come Next?

For a distressed biotech, the decisive events are financial and legal rather than clinical: the outcome of any restructuring, wind-down or Insolvency process; the fate of its pipeline assets, which could be sold or out-licensed; and whether Equity holders retain any residual value, often little or none in such scenarios.

Any clinical continuation would depend on new funding or a partner willing to take on the programs. Updated filings clarifying the company's legal and financial status would be the most important near-term markers.

Risks to Watch

The risks are acute. Names trading with distress-linked tickers frequently carry a real possibility that common equity is impaired or wiped out. Liquidity is minimal, disclosure may be irregular, and dilution or delisting-related actions are live threats.

Even the clinical Assets face funding and execution risk. In short, AFMDQ combines the ordinary hazards of clinical-stage biotech with the specific dangers of a company in apparent financial distress.

Distress Explains the Quote, Not the Science

Affimed N.V. illustrates how quickly a once-prominent immuno-oncology story can unravel. The steady, floor-level share price reflects distress rather than stability, and no operational catalyst explains recent trading.

Investors examining AFMDQ may want to monitor SEC filings for clarity on the company's restructuring or insolvency status, the disposition of its AFM13 and AFM24 assets, and any statement on residual equity value, the factors that will determine whether anything remains for common holders.